Natera, Inc. (NASDAQ:NTRA) Shares Bought by Public Employees Retirement Association of Colorado

Public Employees Retirement Association of Colorado increased its stake in Natera, Inc. (NASDAQ:NTRA) by 14.3% in the second quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 11,915 shares of the medical research company’s stock after buying an additional 1,489 shares during the quarter. Public Employees Retirement Association of Colorado’s holdings in Natera were worth $1,290,000 as of its most recent filing with the SEC.

Other hedge funds have also modified their holdings of the company. Principal Securities Inc. acquired a new stake in Natera in the fourth quarter valued at approximately $32,000. GAMMA Investing LLC increased its stake in Natera by 50.0% during the 2nd quarter. GAMMA Investing LLC now owns 324 shares of the medical research company’s stock worth $35,000 after buying an additional 108 shares during the period. YHB Investment Advisors Inc. acquired a new position in Natera in the 1st quarter worth $36,000. Tobam purchased a new position in Natera in the 2nd quarter valued at about $74,000. Finally, DekaBank Deutsche Girozentrale acquired a new stake in shares of Natera during the first quarter valued at about $83,000. 99.90% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity

In related news, CEO Steven Leonard Chapman sold 37,500 shares of the stock in a transaction that occurred on Monday, July 1st. The stock was sold at an average price of $108.10, for a total value of $4,053,750.00. Following the completion of the transaction, the chief executive officer now directly owns 213,351 shares of the company’s stock, valued at approximately $23,063,243.10. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. In other news, CEO Steven Leonard Chapman sold 37,500 shares of the firm’s stock in a transaction on Monday, July 1st. The stock was sold at an average price of $108.10, for a total transaction of $4,053,750.00. Following the transaction, the chief executive officer now directly owns 213,351 shares of the company’s stock, valued at $23,063,243.10. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Jonathan Sheena sold 12,000 shares of the company’s stock in a transaction dated Thursday, August 15th. The stock was sold at an average price of $121.01, for a total transaction of $1,452,120.00. Following the completion of the sale, the insider now directly owns 287,441 shares of the company’s stock, valued at approximately $34,783,235.41. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 93,921 shares of company stock valued at $10,551,281. Insiders own 7.60% of the company’s stock.

Natera Trading Down 0.4 %

NASDAQ:NTRA opened at $123.08 on Wednesday. The firm has a market capitalization of $15.11 billion, a P/E ratio of -39.45 and a beta of 1.53. The business has a 50 day simple moving average of $114.84 and a 200 day simple moving average of $106.00. The company has a debt-to-equity ratio of 0.34, a current ratio of 4.14 and a quick ratio of 4.01. Natera, Inc. has a 12-month low of $36.90 and a 12-month high of $132.01.

Natera (NASDAQ:NTRA) last released its quarterly earnings results on Thursday, August 8th. The medical research company reported ($0.30) EPS for the quarter, topping the consensus estimate of ($0.69) by $0.39. The business had revenue of $413.35 million during the quarter, compared to analyst estimates of $343.00 million. Natera had a negative net margin of 21.47% and a negative return on equity of 36.74%. The company’s quarterly revenue was up 58.1% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($0.97) earnings per share. Equities research analysts predict that Natera, Inc. will post -1.96 EPS for the current year.

Analyst Upgrades and Downgrades

Several research firms recently commented on NTRA. Piper Sandler reiterated an “overweight” rating and issued a $150.00 price target on shares of Natera in a research note on Friday, September 13th. Morgan Stanley increased their target price on Natera from $125.00 to $132.00 and gave the company an “overweight” rating in a research note on Tuesday, August 13th. UBS Group cut their price target on shares of Natera from $160.00 to $145.00 and set a “buy” rating on the stock in a report on Friday, August 9th. TD Cowen raised their price objective on shares of Natera from $137.00 to $145.00 and gave the stock a “buy” rating in a report on Friday, August 9th. Finally, StockNews.com lowered shares of Natera from a “hold” rating to a “sell” rating in a research note on Wednesday, August 28th. One research analyst has rated the stock with a sell rating and fifteen have issued a buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $120.07.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.